Overview
Portfolio
More
Acorn Bioventures
New York, United States
Acorn Bioventures invests in private and small‑cap biotech, specialty pharma and medical device companies across the full financing spectrum, from seed and cross‑over rounds to IPOs and PIPEs. Their focus is on paradigm‑...
Portfolio
16+
Employees
N/A
Founded
2017
AUM
≈ $200.0M
Investment focus
Stages
Seed → Series C+
Industries
BiotechnologyMedical Devices
Geographic scope
United States
Fund details
Funds
Acorn Bioventures
Vintage 2020
Sources
Acorn Bioventures
Acorn Bioventures invests in private and small‑cap biotech, specialty pharma and medical device companies across the full financing spectrum, from seed and cross‑over rounds to IPOs and PIPEs. Their focus is on paradigm‑changing therapies backed by strong scientific data and outstanding teams, providing capital and long‑term partnership through multiple financing rounds.
Portfolio
16+
Employees
N/A
Founded
2017
AUM
≈ $200.0M
Funds
Acorn Bioventures · Vintage 2020
Stages
Seed → Series C+
Industries
BiotechnologyMedical Devices
Geographic scope
United States
Sources
Showing 8 of 8 matched portfolio companies
Ascendis Pharma is a biopharmaceutical company developing novel therapies utilizing its proprietary TransCon technology platform. The company focuses on advancing product candidates in Endocrinology Rare Disease and Oncology through clinical development. This technology aims to improve treatment safety, efficacy, tolerability, and convenience for patients with unmet medical needs.
BioAtla develops Conditionally Active Biologics (CABs) that are engineered to activate selectively in the tumor microenvironment, enhancing tumor selectivity and reducing on-target toxicity. This technology aims to improve the therapeutic index of cancer treatments, providing safer and more effective immunotherapies.
Funding: $9.2M
Rough estimate of the amount of funding raised
Funding: $9.2M
Rough estimate of the amount of funding raised
CG Oncology develops Cretostimogene, an intravesically delivered oncolytic immunotherapy for non‑muscle invasive bladder cancer (NMIBC). The therapy uses a genetically engineered virus to directly lyse tumor cells and stimulate a systemic immune response, aiming to reduce recurrence and preserve the bladder. It is being evaluated in a comprehensive clinical program for safety and efficacy, targeting urologists, oncologists, and healthcare systems seeking bladder‑sparing treatments.
Funding: $238.0M
Rough estimate of the amount of funding raised
Funding: $238.0M
Rough estimate of the amount of funding raised
Neuron23 develops precision medicines targeting genetically defined neurological diseases, specifically Parkinson's and Alzheimer's, by utilizing advanced data science and human genetics to identify novel molecular targets. Their approach aims to create effective treatments that address the unmet medical needs of patients suffering from these debilitating conditions.
Funding: $213.5M
Rough estimate of the amount of funding raised
Funding: $213.5M
Rough estimate of the amount of funding raised
ONK Therapeutics develops off‑the‑shelf, genetically engineered natural killer (NK) cell therapies that are optimized for enhanced tumor homing, persistence, and resistance to exhaustion. Their proprietary platform creates dual‑targeted NK cells with modifications such as CISH knockout, enabling simultaneous recognition of multiple cancer antigens and scalable, rapid deployment for solid and hematologic tumors. The therapies are designed for integration with other modalities, including bispecific antibodies, to improve anti‑cancer efficacy.
Funding: $21.5M
Rough estimate of the amount of funding raised
Funding: $21.5M
Rough estimate of the amount of funding raised
OnKure Therapeutics discovers and develops tumor‑agnostic small‑molecule therapies that target shared oncogenic driver mutations across cancer types. It leverages pan‑cancer genomic mining, structure‑based drug design, and preclinical models (PDX, organoids) to validate compounds and co‑develop companion diagnostics, enabling biomarker‑driven adaptive trials for oncology clinicians and pharmaceutical partners.
Q32 Bio develops targeted biotherapeutics that re-regulate immune function to treat severe autoimmune and inflammatory diseases. Their lead candidates, Bempikibart and ADX-097, are designed to modulate adaptive and innate immune responses, respectively, addressing conditions such as atopic dermatitis and ANCA-Associated Vasculitis.
Funding: $42.0M
Rough estimate of the amount of funding raised
Funding: $42.0M
Rough estimate of the amount of funding raised
Y-mAbs is a clinical-stage biopharmaceutical company developing antibody immunotherapies targeting rare pediatric cancers, including neuroblastoma and osteosarcoma. Their treatments aim to improve survival rates and safety for patients facing these challenging conditions through ongoing clinical trials.
Funding: $115.0M
Rough estimate of the amount of funding raised
Funding: $115.0M
Rough estimate of the amount of funding raised
Showing 8 of 8 unmatched portfolio companies